Introduction
The American Medical Association (AMA) is a well-known organization that plays a key role in shaping health care policy in the United States. It was accompanied by significant challenges in maintaining membership and influence over a long period. This has motivated the AMA to launch strategic initiatives, including a marketing partnership with Sunbeam Corporation. This essay aims to analyze the risks inherent in AMA-Sunbeam and explore effective strategies for eliminating them.
The result of this paper should be the development of two clear plans built from potential management strategies. They will be the driving forces in mitigating identified risks and preserving the organization’s reputation. By carefully examining these factors, this essay aims to provide valuable insight into the complex dynamics surrounding the AMA’s strategic decisions and their implications for healthcare stakeholders. The identified risks associated with the AMA-Sunbeam partnership suggest that the deal may need to be dismantled to safeguard the American Medical Association’s reputation and uphold its commitment to ethical conduct in healthcare.
Identified Risks
The partnership between the AMA and Sunbeam Corporation creates several risks that should be carefully considered. Collaboration provides a useful framework for many opportunities, but it is important to be aware of conflict-of-interest policies (Rosenblatt & Jain, 2017). First, it poses a risk to the AMA’s reputation and integrity, as cooperation with a corporation known for aggressive restructuring practices can tarnish the AMA’s image. Such practices, notably led by “Chainsaw Al” Dunlap, may tarnish the AMA’s reputation as a trusted authority in health care (Nanda, 2002). Sunbeam has a rather controversial history, which may prompt stakeholders to question the AMA’s commitment to ethical standards.
Second, the agreement may lead to a conflict of interest. The AMA may risk being perceived as an organization that prioritizes financial gain over patient interests (Nanda, 2002). Such a perception could undermine the AMA’s credibility and public confidence in its advocacy efforts. Stakeholders may question the motives behind the approval, thereby undermining the AMA’s independence and commitment to unbiased improvement of health outcomes. Third, there is a tangible risk of legal ramifications associated with endorsing Sunbeam products (Nanda, 2002).
A major risk for the AMA is facing lawsuits for negligence or misrepresentation if these products are found to be harmful. It is worth noting that the legal field poses not only financial risks but also reputational damage and, in general, greater distrust toward the medical field. This is a reason for the AMA to assess and eliminate risks to its own safety and the effectiveness of the primary mission. Among the identified risks, reputation damage and conflict of interest are the most convincing. They were identified as those that would most negatively affect the organization, undermine its authority and influence, and its ability to protect the interests of doctors and patients effectively.
Management of Selected Risks
Several strategies can be employed to manage the risks associated with the AMA-Sunbeam deal effectively. The first involves conducting an AMA thorough review and evaluation of Sunbeam products. This will ensure they meet high-quality standards and will not harm consumers. To do this, the best practice for this organization would be to create an independent advisory group to evaluate the effectiveness and safety of approved products.
The second strategy for the AMA concerns the need for transparency about the financial aspects of the deals. The organization must disclose any potential conflict of interest to its members and the public. Clear communication and adherence to ethical principles are essential to maintaining trust and authority (Nanda, 2005). The third strategy is about hard, clear, and profitable deals with Sunbeam. They must clearly define the terms of product approval, quality control procedures, and conflict resolution mechanisms. This legal framework can help reduce the risk of lawsuits and protect the AMA’s interests.
Selected Management Plans
The AMA acknowledges the imperative of mitigating the risks associated with collaborating with Sunbeam Corporation. According to Nanda (2002), “The AMA’s code of ethics, renamed the principles of medical ethics in 1903, set standards of honesty relative to patient care, guaranteed patient confidentiality, and discouraged the advertisement of proprietary products” (p. 4). To adhere to this, a series of proactive management strategies must be implemented.
Two pivotal plans have been selected, focusing on stringent product assessment and transparent financial disclosure. A rigorous product evaluation entails establishing an independent panel of specialists to assess the scientific validity and safety of Sunbeam products before AMA endorsement. This initiative underscores the AMA’s unwavering dedication to upholding high-quality standards and safeguarding public health. The panel will comprise experts representing various medical and scientific fields who will meticulously scrutinize the efficacy, safety, and potential hazards of Sunbeam products.
The plan to increase transparency in financial disclosures is important to maintaining the AMA’s integrity and accountability. This plan contains open disclosure of the financial terms of the agreement with Sunbeam, including royalty payments, license agreements, and any potential conflicts of interest (Nanda, 2002). Its implementation will ensure transparency of financial aspects, demonstrating the company’s commitment and accountability to its members and the public. Members will have access to comprehensive information about financial arrangements, enabling them to make informed judgments about AMA actions and decisions.
By disclosing financial arrangements, the AMA will be able to eliminate unforeseen biases and motives. In this way, the approval of Sunbeam products will be easier to obtain while maintaining reliability and trust. This transparency also fosters a culture of openness and accountability within the organization, strengthening its commitment to ethical principles and responsible governance (Taştan & Davoudi, 2019). Overall, thorough product evaluation and transparency in financial disclosure are important pillars of risk management for the AMA and Sunbeam partnership. In implementing these plans, the AMA demonstrates its commitment to the highest standards of integrity, quality, and transparency in its interactions with corporate partners and stakeholders.
Likelihood of Acceptance
The AMA is strongly committed to ethical conduct and maintaining public trust. The organization’s management will likely approve the proposed management plans. Rigorous product evaluation resonates with the AMA’s mission to prioritize patient welfare and uphold professional standards (Nanda, 2002).
The commitment to transparency in financial disclosure also reflects the AMA’s core values. An example is their commitment to integrity and accountability, which are critical to maintaining trust in the medical community. With a foundation grounded in ethical principles and public trust, AMA leadership is likely to approve proposed management plans that are consistent with the organization’s commitment to excellence and accountability.
Conclusion
In conclusion, the AMA and Sunbeam deal is problematic and poses significant risks to the AMA’s reputation and integrity. However, effective management of existing risks and compliance with ethical standards suggest the development of plans to mitigate the consequences. This includes guidelines such as rigorous product evaluation, transparent financial disclosure, and reliable contractual agreements. By implementing such proactive measures, the AMA can protect its mission and credibility. This also simultaneously allows the organization to defend the interests of both doctors and patients. This will ensure a commitment to excellence and trust among the medical community.
References
Nanda, A. (2005). The American Medical Association. Harvard Business School.
Nanda, A. (2002). The American Medical Association-Sunbeam deal (A): Serpent on the staff meets chainsaw Al. Harvard Business School.
Rosenblatt, M. & Jain, S. H. (2017). Article ethics: Conflict-of-interest rules are holding back medical breakthroughs. Harvard Business Review.
Taştan, S. B. & Davoudi, S. M. M. (2019). The relationship between socially responsible leadership and organisational ethical climate: In search for the role of leader’s relational transparency. International Business of Governance and Ethics, 13(3), 275-299.